Orlando, FL -- (SBWIRE) -- 10/29/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Celgene Corporation (NASDAQ:CELG), Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Celgene Corporation (NASDAQ:CELG) shares gained 0.31% to $156.23. Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), on oct. 28 presented phase II trial (BCT-001) results of apremilast, the Company's first-in-class, oral, targeted inhibitor of phosphodiesterase 4 (PDE4), in patients with Behçet's disease. The findings were presented at the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting in San Diego.
Additionally, the company on Oct. 24 posted double-digit sales growth in the third quarter, driven by bigger demand for its cancer drugs, even as its earnings fell 12% due to acquisition and restructuring costs. The company reported a profit of $372 million, or 87 cents a share, which exceeded analysts' estimates but was down from $424 million, or 97 cents a share, a year earlier. Excluding certain items, adjusted earnings were up at $1.56 from $1.29. Revenue increased 18% to $1.67 billion.
Are investors worried about the recent updates with CELG? Find out with a free trend analysis HERE
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares declined 4.46% to $23.55. The company on Oct. 21 announced that data from two of its clinical programs, the Phase 1 dose-escalation CDX-1127 study and the Phase 2 recurrent rindopepimut study, will be presented at two upcoming medical meetings, the Society for Immunotherapy of Cancer (SITC) and the Society of Neuro-Oncology (SNO), respectively. The Company also announced its communication plan around these data presentations.
Is CLDX going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)